Special Reports in Personalized Cancer Care Articles

Precision Medicine Moves Forward, 1 Validated Biomarker at a Time
This commentary from Maurie Markman, MD, highlights a critical required component for the development of effective novel antineoplastic strategies through the process widely known as precision cancer medicine.
Jonathan C. Trent, MD, PhD, discusses Sylvester Comprehensive Cancer Center’s ongoing efforts to advance the precision medicine process to improve patient care.
The so-called butterfly effect, in which a small creature can cause something on the scale of an earthquake merely by flapping its wings, is fodder for debate on whether the digital revolution in medicine can deliver on its promise for precision medicine.
Assays Break New Ground in Oncology
Two novel imaging agents and 6 clinical assays for use in cancer care gained the FDA's approval in 2016, marking advances in the diagnostic field.

In recent years, advancements in the treatment of patients with metastatic melanoma have proceeded in 2 areas: targeted therapies and immunotherapies.

Two of the most noteworthy developments in the oncology field during 2016 were the continued expansion of checkpoint blockade immunotherapy agents into more cancer types and the federal government’s plans for funding and remaking the research paradigm.
Although T cells have commanded most of the attention in the burgeoning immuno-oncology field, there is a growing appreciation that other immune cells have important roles in tumor surveillance and would represent attractive therapeutic targets.

Negative reports evaluating molecularly selected agents should not derail the process of developing future therapies by employing a precision medicine approach.

In neuro-oncology, newfound interest has sparked investigations into metabolic pathways in tumors with the hope of identifying novel therapeutic targets.
MSKCC Collaborates With Hackensack Meridian Health in Precision Medicine
To great fanfare, Hackensack Meridian Health of New Jersey and Memorial Sloan Kettering Cancer Center announced a co-branding partnership that they say would lead to highly fruitful collaborative research and make hundreds of clinical trial opportunities available to their patients.
Publication Bottom Border
Border Publication